Follow-up >2 years (N=37)
Dopamine agonists (DA) effectively normalize prolactin (PRL) secretion and reduce tumour size in most patients with macroprolactinomas. However, some patients have partial or discordant responses to treatment, while others are considered resistant. Although treatment adjustments are usually made according to prolactin secretion, the importance of tumor shrinkage in this decision and when the therapeutic response should be expected must be clarified. It would also be important to establish what is a trully resistant macroprolactinoma, the ideal duration of medical treatment and the role of surgery as an adjuvant therapy in the non responders. The aim of this study was to assess the response of macroprolactinomas to DA based on prolactin secretion and tumour size in a cohort of patients treated in our hospital. As expected, in our cohort of patients DA were effective. After 1 year significant differences between "Sensitive" and "PR" groups were detected. In the majority of "Sensitive" patients PRL normalization had already occurred and the second year was important for tumour reduction. "PR" patients needed more time of treatment to achieve therapeutic goals and globally the DA dose titration was slow. The early identification of these individuals might be important to increase the dose or change the therapy. In the small group of "Resistant" patients, despite prolonged treatment, there was no clinical improvement. However, surgery was successful and recurrence did not occur. DA suspension was only possible in 4 "Sensitive" postmenopausal women and in 2 "Resistant" operated patients. 
